Ivabradine Teva

Ivabradine, the active ingredient in Ivabradine Teva, is a If channel inhibitor presented as an oral tablet for oral use. It lowers heart rate and is employed in the management of chronic stable angina and heart failure in adults.

GNH USA supplies Ivabradine Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradine acts on the cardiac If current to control heart rate in conditions where reduced myocardial oxygen demand is beneficial.

Chronic stable angina: reduces the frequency of angina attacks by lowering heart rate without affecting contractility. Heart failure with reduced ejection fraction: improves symptoms and may decrease hospitalisations by maintaining a lower resting heart rate. Sinus rhythm tachycardia: provides heart‑rate control when beta‑blockers are contraindicated or insufficient.

Ivabradine is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Bradycardia: heart rate falls below the intended therapeutic range. - Visual disturbances (phosphenes): transient luminous phenomena, especially in low‑light conditions. - Headache: mild to moderate intensity. - Dizziness or vertigo. - Fatigue or general weakness. - Blurred vision.

Serious or Rare Side Effects: - Symptomatic bradycardia requiring medical intervention. - Atrial fibrillation or other supraventricular arrhythmias. - Severe hypotension. - High‑grade atrioventricular block. - Persistent visual impairment. - Severe allergic reactions such as rash, angioedema, or anaphylaxis.

Before initiating therapy, clinicians should assess cardiac status and concomitant medications. - Severe bradycardia: avoid use in patients with resting heart rate <50 bpm. - Concomitant beta‑blockers or calcium‑channel blockers: monitor for excessive heart‑rate reduction. - Strong CYP3A4 inhibitors: dose adjustment or avoidance may be required. - Hepatic impairment: consider reduced dosing in moderate to severe liver disease. - Pregnancy and lactation: safety not established; use only if potential benefit justifies risk. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Ivabradine may interact with several drug classes, necessitating careful review.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): markedly increase ivabradine exposure. - Other heart‑rate lowering agents (beta‑blockers, digoxin, diltiazem): risk of profound bradycardia. - Concomitant drugs that cause QT prolongation: may exacerbate arrhythmic risk.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole): may modestly raise plasma levels. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Antihypertensives: monitor blood pressure and heart rate for additive effects.